Welcome to the Club

By joining our Early Backers Club you are partaking in the last funding round preceding our scheduled raise for a Series A by end of 2020- which will come from VCs and Institutional funds.  

As we move into the space of AI and file a patent for our AI system, the company’s valuation will inevitably increase, giving our current and existing investors a chance to maximise their returns on their share ownership from this round.


We believe that revealing specific information encoded
within the DNA can help individuals take a step forward towards a personalised healthy living and have an accurate and more successful treatment and fitness regimen.

We believe that:
Genotype + Environment = Phenotype.

Physical characteristics are the result of a complex interaction between genes and environmental factors, and to make a sensible and actionable insight from Genetic information, we:

A.    Engage a qualified partner specialist whenever a clinical report is set to be sent out to one of our patients, in order to provide an accurate and actionable interpretation.

B.    Maintain the highest level of quality and privacy in our service.

C.    Communicate information in an understandable and UI friendly manner to the general public, whilst presenting information that is appropriate for further medical advice.

The Story so far..

The need

It all started with a drug complication that Rightangled’s co-founder saw first hand in her family. Floriane's relative was experiencing drug side effects and responding poorly to an anticoagulant drug. The medication was Plavix (Clopidogrel) and the side effects were gum bleeding and bruises. After seeing her relative survive 5 strokes, it was clear that the drug was not working and a personalised treatment regimen was needed.

NHS funding and support

With Abdullah's knowledge about genetics and its influence on the way we respond to drugs, him and Flo decided to make genetic information more readily available. The concept of a new service design was born, to enable the use of genetic information within the medical practice, in an accurate, streamlined and affordable way. The Heart DNA Test project was later presented to one of the NHS innovation adoption arms in the West Midlands, and it later received the backing and funding from NHS England.

Heart DNA Test launch

Heart DNA testing service was launched in mid 2017 and ever since, it has been helping private practices around London and abroad to remove patient-physician communication barriers, helping patients minimise their cardiac risks and reach their optimal treatment regimen faster, and for doctors to have a complete risk profile for their patients that is objective and evidence-based.

Fitness DNA Test launch

In early 2019, Rightangled fully launched its second specialised genetic testing service that tapped into the fitness and wellbeing markets. The new testing service expanded the company's transatlantic operations with a second branch that later opened in Austin, Texas.

Board of Directors

Joined by our passion for health & innovation

Mr Anas Abuyazid

Non Executive Director

A seasoned banker with Environmental, Social, and Governance (“ESG”) interest. A believer in sustainability. An angel investor across multiple sectors and jurisdictions.

Mr Usman Ahmed

Non-Executive Director

A Surgeon and Nationally appointed Clinical Leadership Fellow with the British Orthopaedic Association. Also, an NHS Clinical Entrepreneur in technological platforms that improve clinicians’ collegiality and enhance patient experience.

Dr Anna Beleza

Clinical Advisor

Locum Clinical Genetics Consultant at Guy's and St Thomas' NHSFoundation Trust. Dr Ana helped review the accuracy of our first product reports “Heart DNA Test”.

Dr Leema Roberts

Clinical Advisor

Cardiac Genetics Consultant at Guy's and St Thomas' NHS Foundation Trust. Dr Leema helped review the accuracy of our first product reports “Heart DNA Test”.

Mr Abdullah Sabyah

Chairman and CEO

A scientist-entrepreneur and a healthcare professional, also the CQC registered manager of Rightangled and a member of the British Heart Foundation Alliance, a member of the Clinical Pharmacogenomics Implementation Consortium in the US, and the inventor of a patent pending-technology for nucleic acid testing on a lateral flow assay.

Dr Sibtain Anwar

Non- Exec

Dr Sibtain Anwar a Senior Lecturer and Consultant in the Department of Perioperative Medicine at the Barts Heart Centre - Europe’s largest cardiovascular institution. He also sits on the Pain Medicine Council at the Royal Society of Medicine. He completed clinical training at Imperial College London, while also pursuing his research interests as an Honorary Fellow of the Academic Cardiology Unit at The National Heart and Lung Institute.

Professor Sir John Cunningham


Lead Scientific Advisor, frontline NHS clinician at The Royal Free Hospital and Professor of Nephrology at UCL Medical School. Active researcher with over I00 papers published in peer reviewed journals. Honorary Fellow of Trinity Hall, University of Cambridge.

Dr Ahmed Merghani


Ahmed graduated from Barts and the London Medical School in 2005, having also accomplished an intercalated BMedSci (hons) degree in Molecular Therapeutics. He attained membership of the Royal College of Physicians in 2008 and went on to achieve a National training number in Cardiology at the West Midlands Deanery. Since then, he has worked as a cardiology registrar in Birmingham and Coventry. In 2012, he pursued an MD degree at St. George’s, University of London.